154 related articles for article (PubMed ID: 35850747)
1. Chronopharmacology of immune-related diseases.
Ohdo S; Koyanagi S; Matsunaga N
Allergol Int; 2022 Oct; 71(4):437-447. PubMed ID: 35850747
[TBL] [Abstract][Full Text] [Related]
2. Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption.
Ohdo S
Adv Drug Deliv Rev; 2010 Jul; 62(9-10):859-75. PubMed ID: 20188774
[TBL] [Abstract][Full Text] [Related]
3. Chronopharmacological strategies focused on chrono-drug discovery.
Ohdo S; Koyanagi S; Matsunaga N
Pharmacol Ther; 2019 Oct; 202():72-90. PubMed ID: 31173839
[TBL] [Abstract][Full Text] [Related]
4. Implications of biological clocks in pharmacology and pharmacokinetics of antitumor drugs.
Ohdo S; Koyanagi S; Matsunaga N
J Control Release; 2023 Dec; 364():490-507. PubMed ID: 37918485
[TBL] [Abstract][Full Text] [Related]
5. Chronopharmacology focused on biological clock.
Ohdo S
Drug Metab Pharmacokinet; 2007 Feb; 22(1):3-14. PubMed ID: 17329905
[TBL] [Abstract][Full Text] [Related]
6. Chrono-Drug Discovery and Development Based on Circadian Rhythm of Molecular, Cellular and Organ Level.
Ohdo S
Biol Pharm Bull; 2021; 44(6):747-761. PubMed ID: 34078807
[TBL] [Abstract][Full Text] [Related]
7. Chronopharmaceutics: pharmaceutics focused on biological rhythm.
Ohdo S
Biol Pharm Bull; 2010; 33(2):159-67. PubMed ID: 20118534
[TBL] [Abstract][Full Text] [Related]
8. [Biological clock and chronopharmacology].
Ohdo S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2007 Jun; 27(3):95-102. PubMed ID: 17633520
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
Pu Y; Ji Q
Front Immunol; 2022; 13():874589. PubMed ID: 35592338
[TBL] [Abstract][Full Text] [Related]
10. Chronobiology in nephrology: the influence of circadian rhythms on renal handling of drugs and renal disease treatment.
De Lavallaz L; Musso CG
Int Urol Nephrol; 2018 Dec; 50(12):2221-2228. PubMed ID: 30324579
[TBL] [Abstract][Full Text] [Related]
11. Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety.
Ohdo S
Drug Saf; 2003; 26(14):999-1010. PubMed ID: 14583062
[TBL] [Abstract][Full Text] [Related]
12. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
13. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
14. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
15. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
16. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
18. Chronopharmacological strategies: Intra- and inter-individual variability of molecular clock.
Ohdo S; Koyanagi S; Matsunaga N
Adv Drug Deliv Rev; 2010 Jul; 62(9-10):885-97. PubMed ID: 20638941
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
